Dysentery

Summary

Dysentery (MONDO:0001517) is a disease with 3 GWAS associations across 2 studies and 31 clinical trials. Top therapeutic interventions include loperamide and rifaximin. A subtype of inflammatory diarrhea — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 3
• Clinical trials: 31

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dysentery
Mondo ID	MONDO:0001517
EFO	EFO:1001869
MeSH	D004403
DOID	DOID:12384
SNOMED CT	111939009, 19213003
UMLS	C0013369
MedGen	3934
Is cancer (heuristic)	no

Also known as: diarrheal disease, infectious · dysenteric diarrhea · dysenteric diarrhoea · infectious diarrhea · infectious diarrheal disease · infectious diarrheal diseases · infectious diarrhoea · infective diarrhea · infective diarrhoea

Data availability: 3 GWAS associations (2 studies).

Disease family

This is a subtype of inflammatory diarrhea. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › gastrointestinal mucositis › inflammatory diarrhea › dysentery

Subtypes (3): protozoal dysentery, shigellosis, infantile diarrhea

Genetics & variants

GWAS landscape

3 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs190894416	7e-09	TBX20 - HERPUD2	T	2.77
rs143977447	1e-08	LINC03000 - LINC01938	A	1.29

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90018836	Sakaue S	2021	2,733	346,689	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90018616	Sakaue S	2021	411	178,071	A cross-population atlas of genetic associations for 220 human phenotypes.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	1
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs190894416	7	35324908	C>T	0.011	intron_variant	TBX20 - HERPUD2	7e-09	Tier 4: intronic/intergenic
rs143977447	5	165219146	C>A,T		intergenic_variant	LINC03000 - LINC01938	1e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Rifamycin.

Clinical trials & evidence

Clinical trials

Clinical trials: 31.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE3	4
PHASE2	4
PHASE1	3
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00490932	PHASE4	COMPLETED	New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management- Surveillance Study for Adverse Effects
NCT06237452	PHASE3	RECRUITING	VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06838195	PHASE3	ACTIVE_NOT_RECRUITING	Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
NCT02280044	PHASE2/PHASE3	COMPLETED	Efficacy of Rifaximin in Preventing Campylobacteriosis
NCT05156528	PHASE3	UNKNOWN	Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
NCT05722119	PHASE3	UNKNOWN	GastroIntestinal Panel in Kidney Transplant Patients
NCT07433426	PHASE2	RECRUITING	The Impact of Shigellosis and Recommended Treatment in Children
NCT01080716	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
NCT03447821	PHASE2	COMPLETED	Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea
NCT04865497	PHASE2	COMPLETED	Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old
NCT05933525	PHASE2	COMPLETED	Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model
NCT03561181	PHASE1	COMPLETED	Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT05409196	PHASE1	COMPLETED	Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
NCT06896136	PHASE1	COMPLETED	Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA
NCT05166850	Not specified	RECRUITING	Preventative Intervention for Cholera for 7 Days
NCT06498817	Not specified	RECRUITING	Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)
NCT07195006	Not specified	RECRUITING	Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories
NCT07538531	Not specified	NOT_YET_RECRUITING	The Utility and Feasibility of Accessible Diarrhea Etiology Prediction Tool (ADEPT) in an Informal Healthcare Setting
NCT01082107	Not specified	COMPLETED	Solar Disinfection of Drinking Water
NCT01306383	Not specified	COMPLETED	Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations
NCT01618591	Not specified	TERMINATED	Trial Evaluating Ambulatory Treatment of Travelers’ Diarrhea
NCT01638039	Not specified	UNKNOWN	Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections
NCT01672580	Not specified	COMPLETED	Social Network Interventions in Rural Honduras
NCT03809117	Not specified	TERMINATED	Film Array Gastrointestinal Panel Compared to Usual Care for ED Evaluation of Infectious Diarrhea
NCT04312906	Not specified	COMPLETED	A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
NCT04423159	Not specified	COMPLETED	Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM)
NCT04602676	Not specified	COMPLETED	The Acceptability and Impact of Diarrheal Etiology Prediction (DEP) Algorithm
NCT05008640	Not specified	COMPLETED	Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
NCT05770726	Not specified	UNKNOWN	Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients
NCT07257705	Not specified	COMPLETED	Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital
NCT07342088	Not specified	COMPLETED	Lactobacillus Acidophilus and Limosilactobacillus Reuteri for Acute Diarrhea in Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LOPERAMIDE	4	3
RIFAXIMIN	4	1